Struyker-Boudier H A, Nievelstein H M, Smits J F
Department of Pharmacology, University of Limburg, Maastricht, The Netherlands.
J Hypertens Suppl. 1985 Dec;3(3):S183-6.
The acute haemodynamic and long-term antihypertensive properties of the renal vasodilator pro-drug CGP 22 979A (N-acetyl-L-glutamic acid-N-[N2-(5-n-butyl-2- pyridyl)-hydrazide]) were studied in conscious, chronically instrumented spontaneously hypertensive rats (SHR). Its effects were compared with those of its parent substance CGP 18 137A (2-hydrazino-5-n-butyl-pyridine) which is a general arteriolar dilator. CGP 18 137A (0.3-1 mg/kg) caused an immediate reduction in mean arterial pressure (MAP) and total peripheral resistance index (TPRI). These effects were paralleled by reflex increases in heart rate (HR) and cardiac index (CI). In high doses CGP 22 979A (30 mg/kg) caused similar effects. In contrast, lower doses of CGP 22 979A (3-10 mg/kg) did not reduce MAP or TPRI acutely. However, these doses caused a more gradual reduction in MAP without reflex increase in HR or CI. In long-term experiments a 7-day continuous infusion of CGP 18 137A (0.1-1 mg/kg per day) or a high rate of CGP 22 979A (30 mg/kg per day) reduced MAP with parallel reflex rises in HR. Ten mg/kg per day CGP 22 979A caused a gradual reduction in MAP without reflex tachycardia.
在清醒的、长期植入仪器的自发性高血压大鼠(SHR)中,研究了肾血管扩张前体药物CGP 22 979A(N-乙酰-L-谷氨酸-N-[N2-(5-正丁基-2-吡啶基)-酰肼])的急性血流动力学和长期降压特性。将其效果与其母体物质CGP 18 137A(2-肼基-5-正丁基吡啶)进行比较,后者是一种一般的小动脉扩张剂。CGP 18 137A(0.3-1毫克/千克)可使平均动脉压(MAP)和总外周阻力指数(TPRI)立即降低。这些作用伴随着心率(HR)和心脏指数(CI)的反射性增加。高剂量的CGP 22 979A(30毫克/千克)产生类似的效果。相比之下,较低剂量的CGP 22 979A(3-10毫克/千克)不会急性降低MAP或TPRI。然而,这些剂量会使MAP更逐渐地降低,而不会使HR或CI反射性增加。在长期实验中,连续7天输注CGP 18 137A(每天0.1-1毫克/千克)或高剂量的CGP 22 979A(每天30毫克/千克)可降低MAP,并伴有HR的平行反射性升高。每天10毫克/千克的CGP 22 979A可使MAP逐渐降低,而不会出现反射性心动过速。